• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Publication

Article

Dermatology Times

Dermatology Times, October 2018 (Vol. 39, No. 10)
Volume39
Issue 10

AIVITA Biomedical names new CFO, VP of business development

AIVITA Biomedical, a biotech firm that focuses on regenerative medicines such as stem cell applications, recently named two new members to its senior management team.

Mr. Burrell

Mr. Burrell

Mr. Green

Mr. Green

AIVITA Biomedical, a biotech firm that focuses on regenerative medicines such as stem cell applications, recently named two new members to its senior management team, according to a company news release.

New chief financial officer Scott Burrell joined from CombiMatrix Corporation, where he also was CFO and helped manage that company’s sale. His background includes 25 years in corporate finance and compliance, working in healthcare, high-tech and biotech fields.

Kevin Green was named AIVITA’s vice president of business development. For 10 years at Allergan, he was senior director of business development, overseeing transactions, including the $2.1 billion Kythera acquisition.

“Mr. Burrell and Mr. Green bring decades of B2B, corporate finance and capital raising experience to AIVITA. These appointments reflect our plans for further capitalization via investment and partnership,” AIVITA Chairman and CEO Hans S. Keirstead, Ph.D., said in a news release.

AIVITA, a privately-held company, also recently made hires to support its ROOT OF SKIN and ROOT OF SKIN MD skincare lines.

Related Videos
Dr. Suneel Chilukuri
 Health Care Impacts on Gender and Sexual Minority Patients
 Caring for Gender and Sexual Minority Patients
© 2024 MJH Life Sciences

All rights reserved.